Meta-analysis of 6 studies (202 patients with non-infectious uveitis): switching from originator adalimumab or infliximab to biosimilars was not linked to more flares (IRR 1.26, 95% CI 0.72–2.21); 30 patients reverted, mostly for injection pain or injector problems.
Meta-analysisn = 202
Zhang et al. Clinical Efficacy of Biosimilar Switch of Adalimumab and Infliximab for Noninfectious Uveitis: Systematic Review and Meta-Analysis